glp-1 obesity drug market forecast 2030 Size, Scope, Report 2026 to 2035 Oral Obesity Drugs Market Size

Monlunabant Name : Monlunabant Manufacturer : Novo Nordisk Current stage: Phase II trials to further investigate dosing and the safety profile of monlunabant over a longer duration in a global population

Hormonal changes , particularly menopause in women and low testosterone in men, frequently cause nocturnal sweating

And people gain the weight back when they come off it. Costs for five of the GLP-1 drugs Ozempic, Mounjaro, Wegovy, Zepbound, and Saxenda topped $300 million for Boston-based Blue Cross last year, more than double what it spent in 2023

In kidney transplants, a slower decline in glomerular filtration rate, which measures kidney function, has been observed compared to other diabetes treatments

Short half-life, pleiotropy, and behavioral or cardiovascular effects were historically interpreted as disqualifying features

GLP-1 medicines are prescription drugs and should only be started after evaluation by a qualified doctor.